Tellgen Corporation announced its exclusive strategic investment in CytoCares (Shanghai) Inc., marking an important milestone in building an integrated “Diagnosis + Therapy” ecosystem in the field of autoimmune diseases. This collaboration aligns with Tellgen’s long-term strategy to extend its diagnostic expertise into therapeutic innovation and strengthen its capability to provide full-cycle healthcare solutions.
Mr. Yao Jian’er, Chairman of Tellgen Corporation, and Dr. Zhuhua Xing, Founder and Chairman of CytoCares (Shanghai) Inc.
Mr. Yao Jian’er, Chairman of Tellgen Corporation
Dr. Huang Yingfeng, CEO of CytoCares
Advancing the “Diagnosis–Therapy–Monitoring” Model
Tellgen has established strong technical and market foundations in autoimmune diagnostics through its flow fluorescence platform, a system recognized by the College of American Pathologists (CAP) for autoimmune antibody proficiency testing. The company offers accurate detection of 46 autoantibody targets, including the 16-item Antinuclear Antibody Panel, Autoimmune Liver Antibody Panel, and 15-item Myositis Antibody Panel.
Tellgen’s autoimmune diagnostic products are trusted by leading hospitals in Shanghai and Beijing and are approved for the precise diagnosis of major autoimmune diseases such as Systemic Lupus Erythematosus (SLE).
Strategic Collaboration with CytoCares
CytoCares has developed a next-generation TriTE™ (Triple T-cell Engager) platform featuring CD28 co-stimulatory signaling, offering unique advantages in autoimmune and oncologic therapies. Its lead candidate, CC312 (CD19/CD3/CD28), has received IND approvals in both China and the United States, including the world’s first IND approval for a CD28 co-stimulatory TCE in SLE.
Early clinical data demonstrate good safety and strong efficacy in patients with moderate to severe SLE, showing significant reductions in disease activity and superior outcomes compared with existing treatments. These findings, presented at AACR and EULAR, provide a solid foundation for further global clinical development.
Through this partnership, Tellgen and CytoCares aim to accelerate the clinical progress of CC312 and other autoimmune indications, expand international collaboration, and bring innovative therapies to patients worldwide.
Mr. Yao Jian’er, Chairman of Tellgen Corporation, stated:
“This investment represents a key step in advancing Tellgen’s ‘Diagnosis–Therapy–Monitoring’ strategy for autoimmune diseases. CytoCares’ innovative TriTE™ platform and its promising CC312 pipeline demonstrate leading global potential. Together, we will drive innovation and deliver new solutions for patients in need.”
Dr. Huang Yingfeng, CEO of CytoCares, commented:
“Tellgen’s strategic vision and strong presence in autoimmune diagnostics perfectly complement CytoCares’ mission to pioneer antibody-based therapies. We are delighted to welcome Tellgen as a strategic partner to accelerate clinical development and commercialization.”
About Tellgen Corporation
Founded in 2003 and headquartered in Zhangjiang Hi-Tech Park, Shanghai, Tellgen Corporation (300642.SZ) specializes in the R&D, manufacturing, and marketing of advanced in vitro diagnostic products. The company has obtained nearly 400 product registrations and built multiple technology platforms, including flow fluorescence, chemiluminescence, multiplex PCR, LC-MS/MS, and pathology.
Tellgen’s products cover tumor monitoring, autoimmune diseases, cardiovascular health, infectious diseases, and reproductive health. Since 2024, the company has actively expanded into integrated diagnosis–therapy development through strategic acquisitions and investments in pathology, medical devices, and therapeutics.
About CytoCares (Shanghai) Inc.
Established in 2015 in Zhangjiang Hi-Tech Park, Shanghai, CytoCares focuses on developing innovative antibody and cell-engaging therapies for cancer and autoimmune diseases. The company has built proprietary TriTE™, CCNK™, and CCMφ™ drug discovery platforms targeting T-cell, NK-cell, and macrophage activation.
Its lead molecule CC312 has entered clinical research and shown promising efficacy in both hematologic malignancies and autoimmune indications. The R&D team, with nearly 20 years of biologics development experience, is committed to becoming a global leader in next-generation multispecific antibody therapeutics.